FDA Warns of 184 Injuries From Recalled Medtronic Device

The U.S. Food and Drug Administration (FDA) issued a public safety communication on Thursday, March 7, 2024, detailing 184 serious injuries linked to recalled Bravo calibration-free (CF) acid-monitoring capsule delivery devices. These devices are designed to assist in the diagnosis of gastroesophageal reflux disease (GERD) by monitoring acid levels in the esophagus. The recall specifically pertains to the delivery devices used to implant the Bravo pH monitoring capsule, not the capsule itself. According to the FDA's alert, the recalled devices have been associated with adverse events that have led to significant patient harm. While the exact nature of all 184 injuries was not fully detailed in the initial warning, the FDA's action underscores a significant safety concern that necessitates immediate attention from healthcare providers and patients who may have undergone procedures involving this device.

Medtronic, the manufacturer of the Bravo pH monitoring system, has been involved in the recall process. The company has stated that it is working with the FDA and healthcare professionals to address the issue. The Bravo pH monitoring system is a widely used diagnostic tool that allows for wireless, ambulatory monitoring of esophageal pH for up to 96 hours. This extended monitoring period provides clinicians with comprehensive data to assess the frequency and duration of acid reflux events, aiding in the diagnosis and management of GERD. The calibration-free nature of the Bravo CF system was intended to simplify the procedure for both clinicians and patients, eliminating the need for in-office calibration after capsule placement. However, the safety concerns raised by the FDA now cast a shadow over the reliability and safety of the delivery mechanism for this technology.

The FDA's warning serves as a critical alert to physicians who perform upper gastrointestinal procedures, particularly those involving esophageal pH monitoring. Healthcare providers are urged to review their inventory of Bravo CF acid-monitoring capsule delivery devices and to cease using any recalled units immediately. Patients who have recently undergone procedures using the Bravo pH monitoring system and are experiencing unusual or severe symptoms should consult their physician. The FDA is actively monitoring the situation and working with Medtronic to ensure that appropriate corrective actions are taken to prevent further harm. The agency emphasized the importance of prompt reporting of any adverse events related to medical devices through its MedWatch program, which helps in identifying and addressing potential safety issues in a timely manner. This incident highlights the ongoing challenges in ensuring the safety and efficacy of medical devices throughout their lifecycle, from design and manufacturing to post-market surveillance and recall management.